Historically there has been one practical option for dealing with interfraction and intrafraction motion during stereotactic body radiotherapy (SBRT): increase the clinical target volume. Doing so, however, can also expose healthy organs and tissue to radiation. But, with FDA clearances for Calypso® Beacon® transponders for soft tissue and lung, clinicians today have a highly precise and effective way to monitor and adapt to tumor movement.
This article profiles three cancer programs that have used Calypso for SBRT:
- Real-time tumor tracking at The University of Kansas Cancer Center: “Like working in the light”
- Tracking lung tumors with precision at the University of Alabama at Birmingham
- Treating in the liver and reducing margins from 10 to 7 millimeters at Aarhus University Hospital
